None listed
Conditions
Brief summary
Insomnia is a prevalent and debilitating disorder in Australia. The recommended treatment for insomnia is Cognitive Behavioural Therapy for insomnia (CBTi). However, there are very few clinicians in Australia with training in CBTi. Consequently, most patients with insomnia never access CBTi. Digital CBTi programs are an effective and potentially scalable intervention to manage insomnia. There are very few evidence-based digital CBTi programs available in Australia, and currently no publicly-available digital CBTi programs that provide personalised weekly behavioural therapy recommendations. This randomised controlled implementation trial aims to investigate the feasibility and effectiveness of a digital CBTi referral pathway in Australian pharmacy settings. Patients that are referred, eligible and consent to participate will be randomised 1:1 to a digital brief cognitive behavioural therapy for insomnia program, versus waitlist education control. It is hypothesised that the group who receive the brief CBTi program will report a reduced severity of insomnia, depression and fatigue symptoms, compared to the group that receive education (waitlist control). • It is hypothesised that the digital CBTi program will be adopted by at least two new pharmacists in Australia per month of the study. • It is hypothesised that at least 50% of pharmacists will refer 3 or more patients to the digital CBTi referral pathway. • It is hypothesised that the intervention group will report a reduced severity of insomnia, depression, and fatigue symptoms from 8-week follow-up, compared to the education control group. • It is hypothesised that insomnia, depression, and fatigue symptom improvements will be sustained by 16-week and 24-week follow-up in the CBTi group.
Interventions
This randomised waitlist-controlled implementation trial will investigate the feasibility and effectiveness of providing Australian pharmacists access to an online referral pathway, to refer their patients to an online Cognitive Behavioural Therapy for Insomnia (CBTi) program. Pharmacists, and a selection of eligible patients they refer to the study will be recruited. Patients referred to the trial by pharmacists will undergo online screening and consent. Eligible patients will complete a baseline questionnaire battery before being randomised 1:1 to a 5-session online CBTi program, or waitlist education-control. Patients will complete outcome questionnaires at 8, 16, and 24 weeks. The waitlist control group will be provided access to the online CBTi program after the 8-week follow-up. With consent from patients, pharmacists and general practitioners will be provided a follow-up report of patient progress at 8, 16, and 24 week follow-up. GP follow-up reports will be generated by the study team and will include participant-level information on; change in insomnia symptoms before and after treatment, sleeping pill use, and date of next follow-up report. Information about the online CBTi program appears below. Rationale: Cognitive behavioural therapy for insomnia (CBTi) is the recommended 'first line' treatment for insomnia (Qaseem et al., 2016, Ann Intern Med). Very few Australian patients with insomnia ever access CBTi (Miller et al., 2017, JCSM). This project aims to test the effectiveness of a dCBTi intervention in the Australian pharmacy settings. Type: Non-drug, online, interactive. Setting/location: Online, any location in Australia. Duration: 5 x 20 minute online sessions, delivered over 5 consecutive weeks. Protocol: This program is based on CBTi, the recommended treatment for insomnia (e.g. Qaseem et al., 2016, Ann Intern Med, DOI: 10.7326/M15-2175). It is an interactive online version of a brief CBTi protocol described in an scientific article in the Australian Journal of General Practice (Sweetman et al., 2021, AJGP, doi: 10.31128/AJGP-04-20-5391). Content: Each session will be administered online (computer or mobile phone). Each session will contain videos, text, and images. Patients will be asked to enter text-based, numerical (e.g. minutes of sleep duration) and multiple-choice data throughout the program. Participants will receive tailored therapy recommendations during each weekly session (see Sweetman et al., 2021, Aus J General Practice for tailored therapy recommendations). Immediately after each session is completed, participants will receive an automated follow-up email with session-specific 'follow-up' information and tailored therapy recommendations including recommended bedtime window (approximate reading time: 15 minutes). Participants will receive another automated email one week later with a link to start each subsequent session. Videos are presented by researchers, psychologists, and sleep technicians, each with extensive experience (>8 years) in the management of insomnia. Tailoring / personalisation: Therapy recommendations will be tailored to participant's insomnia symptoms at baseline and weekly changes in symptoms throughout the program. Bedtime Restriction Therapy (initial restriction of time in bed to consolidate sleep, and subsequent gradual extension of time in bed) is a core component of CBTi. Bedtime restriction recommendations will be tailored to the specific sleep/wake information that participants provide. Primary therapeutic components: Information about sleep, Relaxation therapy, Cognitive restructuring, Bedtime restriction therapy, Stimulus Control Therapy. Adherence assessment: Adherence will be defined as the number of participants commencing each of the 5 online sessions. This information is automatically collected through the online system.
Sponsors
Study design
Eligibility
Inclusion criteria
Pharmacist inclusion criteria: 1. Currently practicing as a pharmacist in Australia. Patient inclusion criteria: 1. Aged at least 18 2. Referred by participating pharmacist. 3. Reliable access to computer, tablet or smartphone, with internet access. 4. Basic English language comprehension as required for dCBTi program participation.
Exclusion criteria
1. No excessive daytime sleepiness (Epworth Sleepiness Scale score score of greater than or equal to 16). 2. None of the following psychiatric conditions; Bi-polar disorder, schizophrenia. 3. No risk of suicide (PHQ-9; item 9 score of greater than or equal to 1). 4. No Epilepsy. 5. Not currently pregnant. 6. No commercial drivers or people who operate heavy machinery for work. 7. No people with a cognitive impairment. 8. No shift-workers. 9. Previous sleepiness-related motor vehicle accident.